GlassScriptPhysician profile
Jennifer M Devine
NPI 1255527610
$281.24
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217 · 2020: $39.12 · 2021: $24.86.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $44.28 | 2019 | |
| Lilly USA, LLC | $44.02 | 2019 | |
| Abbott Laboratories | $42.29 | 2019-2021 | |
| Nevro Corp. | $37.10 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $34.86 | 2019 | |
| Arbor Pharmaceuticals, INC. | $34.05 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $18.22 | 2019 | |
| Assertio Therapeutics, INC. | $15.62 | 2019 | |
| Pernix Therapeutics Holdings, INC. | $10.80 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Devine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.